STAT3 and Familial prostate cancer: Overexpression of STAT3 and its main regulator IL6 is reported in the literature but IL6 inhibitory effect in prostate cancer progression and failure of STAT3-IL6 axis targeting as potential therapeutic target in patients were reported as well.